128 related articles for article (PubMed ID: 2141886)
1. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin.
Lundgren S; Lønning PE
J Steroid Biochem; 1990 Jun; 36(1-2):105-9. PubMed ID: 2141886
[TBL] [Abstract][Full Text] [Related]
2. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings.
Lundgren S; Lønning PE; Utaaker E; Aakvaag A; Kvinnsland S
J Steroid Biochem; 1990 Jun; 36(1-2):99-104. PubMed ID: 2362454
[TBL] [Abstract][Full Text] [Related]
3. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.
Lundgren S; Lønning PE; Aakvaag A; Kvinnsland S
Cancer Chemother Pharmacol; 1990; 27(2):101-5. PubMed ID: 2249324
[TBL] [Abstract][Full Text] [Related]
4. The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
Dowsett M; Lal A; Smith IE; Jeffcoate SL
Br J Cancer; 1987 Mar; 55(3):311-3. PubMed ID: 2952154
[TBL] [Abstract][Full Text] [Related]
5. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones.
Adlercreutz H; Pulkkinen MO; Hämäläinen EK; Korpela JT
J Steroid Biochem; 1984 Jan; 20(1):217-29. PubMed ID: 6231418
[TBL] [Abstract][Full Text] [Related]
6. Adrenal steroids as parameters of the bioavailability of MA and MPA.
Willemse PH; Dikkeschei LD; Tjabbes T; van Veelen H; Sleijfer DT
Eur J Cancer; 1990 Mar; 26(3):359-62. PubMed ID: 2141494
[TBL] [Abstract][Full Text] [Related]
7. Progestational agents in the treatment of breast cancer.
Carpenter JT
Cancer Treat Res; 1988; 39():147-56. PubMed ID: 2908605
[No Abstract] [Full Text] [Related]
8. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatment.
Blackledge GR; Latief T; Mould JJ; Spooner D; Morrison M
Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1091-4. PubMed ID: 2946584
[TBL] [Abstract][Full Text] [Related]
10. Changes in serum sex steroid levels during megestrol acetate therapy.
Pommier RF; Woltering EA; Fletcher WS
Surg Oncol; 1994 Dec; 3(6):351-9. PubMed ID: 7773452
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.
Willemse PH; van der Ploeg E; Sleijfer DT; Tjabbes T; van Veelen H
Eur J Cancer; 1990 Mar; 26(3):337-43. PubMed ID: 2141491
[TBL] [Abstract][Full Text] [Related]
12. [Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study].
Wander HE; Kleeberg UR; Gärtner E; Hartlapp J; Scherpe A; Bönisch E; Nagel GA
Onkologie; 1987 Apr; 10(2):104-6. PubMed ID: 2954006
[No Abstract] [Full Text] [Related]
13. Oral high-dose progestins as treatment for advanced breast cancer.
Lundgren S; Kvinnsland S; Utaaker E
Acta Oncol; 1989; 28(6):811-6. PubMed ID: 2532917
[TBL] [Abstract][Full Text] [Related]
14. Progestational agents in advanced breast cancer: an overview.
Haller DG; Glick JH
Semin Oncol; 1986 Dec; 13(4 Suppl 4):2-8. PubMed ID: 3026051
[TBL] [Abstract][Full Text] [Related]
15. Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancer.
Alexieva-Figusch J; Blankenstein MA; de Jong FH; Lamberts SW
Eur J Cancer Clin Oncol; 1984 Sep; 20(9):135-40. PubMed ID: 6434315
[TBL] [Abstract][Full Text] [Related]
16. Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines.
Cappelletti V; Miodini P; Fioravanti L; Di Fronzo G
Anticancer Res; 1995; 15(6B):2551-5. PubMed ID: 8669822
[TBL] [Abstract][Full Text] [Related]
17. Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer.
Lundgren S; Kvinnsland S; Utaaker E; Bakke O; Ueland PM
Cancer Chemother Pharmacol; 1986; 18(3):270-5. PubMed ID: 2948732
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of estradiol, estrone, estrone sulfate and sex hormone binding globulin in patients receiving rifampicin.
Lønning PE; Bakke P; Thorsen T; Olsen B; Gulsvik A
J Steroid Biochem; 1989 Oct; 33(4A):631-5. PubMed ID: 2811375
[TBL] [Abstract][Full Text] [Related]
19. The role of progestins in the treatment of breast cancer.
Blumenschein GR
Semin Oncol; 1983 Dec; 10(4 Suppl 4):7-10. PubMed ID: 6230722
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
Labrie C; Cusan L; Plante M; Lapointe S; Labrie F
J Steroid Biochem; 1987 Oct; 28(4):379-84. PubMed ID: 2444770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
